Van Poznak Catherine
Memorial Sloan-Kettering Cancer Center, Breast Cancer Medicine Service, New York, New York, USA.
Cancer Invest. 2006 Feb;24(1):110-2. doi: 10.1080/07357900500449652.
Osteonecrosis of the jaw (ONJ) has been noted to occur in patients with cancer receiving bisphosphonate therapy and may also be referred to as bisphosphonate associated osteonecrosis (BON). ONJ has come to attention through case reporting and the pathogenesis and true incidence of this condition are not yet defined. ONJ appears to be a relatively uncommon event, but it is of clinical significance; the evolving data on ONJ are discussed here.
颌骨骨坏死（ONJ）已被注意到发生在接受双膦酸盐治疗的癌症患者中，也可能被称为双膦酸盐相关性骨坏死（BON）。ONJ通过病例报告引起了关注，这种情况的发病机制和真实发病率尚未明确。ONJ似乎是一种相对罕见的事件，但具有临床意义；本文讨论了关于ONJ的不断发展的数据。
